NCT07373470 An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
| NCT ID | NCT07373470 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Pharmacogenetics |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2026-09-09 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 220 participants in total. It began in 2026-09-09 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes. The primary aim is to determine whether comprehensive medication management with review of PGx testing results improves depression symptoms, compared with usual care. Participants 18 years of age or older who have undergone PGx testing (e.g. through an independent biobanking study (Pitt+Me Discovery) who require initiation or adjustment of antidepressant therapy will be randomly assigned to receive either PGx-guided comprehensive medication management or usual care. Those who receive usual care will receive their PGx results at the end of the study. Researchers will compare the groups to assess whether PGx-guided care provided in partnership with community pharmacists and prescribers results in better depression and medication outcomes.
Eligibility Criteria
INCLUSION CRITERIA: * At targeted community pharmacy for: * New prescription or change in dose/schedule of SSRI (citalopram, escitalopram, sertraline, paroxetine), OR * Concurrent SSRI (citalopram, escitalopram, sertraline, paroxetine) and new prescription/change in SNRI (desvenlafaxine, duloxetine, and venlafaxine) / bupropion. * Depressive symptoms confirmed by PHQ8 assessment (\>5 indicating at least mild depressive symptoms) * UPMC patient (or able/willing to become one) and has UPMC provider (or able/willing to obtain one) * Signed consent to join Pitt+Me Discovery biobanking research study. * English-speaking EXCLUSION CRITERIA: * Inability to receive CMM at specific pharmacy/pharmacist * Comorbid diagnosis of schizophrenia (patient-reported) * Untreated sleep disorder (patient-reported) * Pitt+Me Discovery participant who has elected to not receive return of results, or who has already received results previously
Contact & Investigator
Philip E Empey, PharmD, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT07373470 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pharmacogenetics. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07373470 currently recruiting?
Yes, NCT07373470 is actively recruiting participants. Contact the research team at CompassPGx@pitt.edu for enrollment information.
Where is the NCT07373470 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT07373470 clinical trial?
NCT07373470 is sponsored by University of Pittsburgh. The principal investigator is Philip E Empey, PharmD, PhD at University of Pittsburgh. The trial plans to enroll 220 participants.